Primary Biliary Cholangitis is a rare, progressive, chronic autoimmune disease of the liver in which the small bile ducts are gradually destroyed, causing bile and other toxins to build up in the liver (known as cholestasis). Further damage can lead to scarring, fibrosis and eventually cirrhosis of the liver. Ursodeoxycholic acid (UDCA) and Intercept Pharma's Ocaliva are some of the FDA-approved drugs for primary biliary cholangitis.
The company we are profiling today is Genfit S.A. (GNFT) which is also developing a therapeutic for primary biliary cholangitis.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.